» Articles » PMID: 32353163

Real-world Evaluation of the Impact of Statin Intensity on Adherence and Persistence to Therapy: A Scottish Population-based Study

Abstract

Aim: To assess associations between statin intensity and adherence, persistence and discontinuation of statin therapy in Scotland.

Method: Retrospective cohort study, using linked electronic health records covering a period from January 2009 to December 2016. The study cohort included adult patients (≥18 years) newly initiating statins within Greater Glasgow and Clyde, Scotland. Study outcomes comprised adherence, discontinuation and persistence to treatment, stratified by three exposure groups (high, moderate and low intensity). Discontinuation and persistence were calculated using the refill-gap and anniversary methods, respectively. Proportion of days covered (PDC) was used as a proxy for adherence. Kaplan-Meier survival curves and Cox proportional hazard models were used to evaluate discontinuation, and associations between adherence/persistence and statin intensity were assessed using logistic regression.

Results: A total of 73 716 patients with a mean age of 61.4 ± 12.6 years were included; the majority (88.3%) received moderate intensity statins. Discontinuation rates differed between intensity levels, with high-intensity patients less likely to discontinue treatment compared to those on moderate intensity (prior cardiovascular disease [CVD]: HR 0.43 [95% CI 0.34-0.55]; no prior CVD: 0.80 [0.74-0.86]). Persistence declined over time, and high-intensity patients had the highest persistence rates. Overall, 52.6% of patients were adherent to treatment (PDC ≥ 80%), but adherence was considerably higher among high-intensity patients (63.7%).

Conclusion: High-intensity statins were associated with better persistence and adherence to treatment, but overall long-term persistence and adherence remain a challenge, particularly among patients without prior CVD. This needs addressing.

Citing Articles

Trends in statin utilization and ischemic heart disease mortality in Lithuania and Sweden, 2000-2020.

Treciokiene I, Daukintyte K, Hjemdahl P, Wettermark B Ups J Med Sci. 2024; 129.

PMID: 38863727 PMC: 11165250. DOI: 10.48101/ujms.v129.10412.


Statins use amidst the pandemic: prescribing, dispensing, adherence, persistence, and correlation with COVID-19 statistics in nationwide real-world data from Poland.

Kardas P, Kwiatek A, Wlodarczyk P, Urbanski F, Ciabiada-Bryla B Front Pharmacol. 2024; 15:1350717.

PMID: 38655185 PMC: 11035734. DOI: 10.3389/fphar.2024.1350717.


Editorial: Medication safety and interventions to reduce patient harm in low- and middle-income countries.

Mahmoud M, Meyer J, Awaisu A, Fadare J, Fathelrahman A, Saleem F Front Pharmacol. 2023; 13:1124371.

PMID: 36699062 PMC: 9868153. DOI: 10.3389/fphar.2022.1124371.


Bempedoic Acid: The New Kid on the Block for the Treatment of Dyslipidemia and LDL Cholesterol: A Narrative Review.

Alam U, Al-Bazz D, Soran H Diabetes Ther. 2021; 12(7):1779-1789.

PMID: 34037950 PMC: 8266948. DOI: 10.1007/s13300-021-01070-6.


Real-World Effectiveness of Therapy With Rosuvastatin Combined With Fenofibric Acid in a Sample of Colombian Patients With Mixed Dyslipidemia.

Machado-Duque M, Gaviria-Mendoza A, Machado-Alba J J Prim Care Community Health. 2020; 11:2150132720977733.

PMID: 33251941 PMC: 7705806. DOI: 10.1177/2150132720977733.


References
1.
Virani S, Woodard L, Akeroyd J, Ramsey D, Ballantyne C, Petersen L . Is high-intensity statin therapy associated with lower statin adherence compared with low- to moderate-intensity statin therapy? Implications of the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guidelines. Clin Cardiol. 2014; 37(11):653-9. PMC: 6649436. DOI: 10.1002/clc.22343. View

2.
Armstrong S, Little R . Cost effectiveness of interventions to improve adherence to statin therapy in ASCVD patients in the United States. Patient Prefer Adherence. 2019; 13:1375-1389. PMC: 6700656. DOI: 10.2147/PPA.S213258. View

3.
Vrijens B, de Geest S, Hughes D, Przemyslaw K, Demonceau J, Ruppar T . A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012; 73(5):691-705. PMC: 3403197. DOI: 10.1111/j.1365-2125.2012.04167.x. View

4.
Lehmann A, Aslani P, Ahmed R, Celio J, Gauchet A, Bedouch P . Assessing medication adherence: options to consider. Int J Clin Pharm. 2013; 36(1):55-69. DOI: 10.1007/s11096-013-9865-x. View

5.
Wei M, Ito M, Cohen J, Brinton E, Jacobson T . Predictors of statin adherence, switching, and discontinuation in the USAGE survey: understanding the use of statins in America and gaps in patient education. J Clin Lipidol. 2013; 7(5):472-83. DOI: 10.1016/j.jacl.2013.03.001. View